The data shows the CAGR of selected biotechnology companies' market capitalization in the U.S. between 2012 and 2016. During this period, Amgen had a CAGR of 21%. Revenues of the U.S.' biotechnology market has grown over the last 15 years.
Incyte Corporation | 78 |
Regeneron Pharmaceuticals | 67 |
Illumina | 50 |
BioMarin Pharmaceutical | 38 |
Gilead Sciences | 32 |
Celgene | 31 |
Vertex Pharmaceuticals | 27 |
Biogen | 23 |
Amgen | 21 |
Alexion Pharmaceuticals | 20 |